Background: Although studies suggest that omega-3 fatty acids intake may reduce cardiovascular disease (CVD) mortality risk, few studies have differentiated dietary eicosapentaenoic/docosahexaenoic acid (EPA/DHA) from alphalinolenic acid (ALA), and epidemiological research in Asian populations is limited. Methods: The Singapore Chinese Health Study is a population-based cohort that recruited 63,257 Chinese adults aged 45-74 years from 1993 to 1998. Usual diet was measured at recruitment using a validated semiquantitative foodfrequency questionnaire, and mortality information was identified via registry linkage up to 31 December 2011. Cox proportional hazard models were used to calculate hazard ratios (HRs) with adjustment for potential confounders. Results: We documented 4780 cardiovascular deaths (including 2697 coronary heart disease (CHD) deaths and 1298 stroke deaths) during 890,473 person-years of follow up. Omega-3 fatty acids intake was monotonically associated with reduced risk of cardiovascular mortality. Compared to the lowest quartile, the HR was 0.88 (95% confidence interval, CI, 0.81-0.96), 0.88 (95% CI 0.80-0.97), and 0.83 (95% CI 0.74-0.92) for the second, third, and highest quartile, respectively (p-trend ¼ 0.003). Both EPA/DHA and ALA were independently associated with reduced risk of cardiovascular mortality: HR comparing extreme quartiles was 0.86 (95% CI 0.77-0.96, p-trend ¼ 0.002) and 0.81 (95% CI 0.73-0.90, p-trend < 0.001), respectively. The associations were similar for deaths from CHD and stroke and persisted in participants who were free of CVD at baseline. Conclusions: Higher intakes of marine (EPA/DHA) and plant (ALA) omega-3 fatty acids are both associated with reduced risk of cardiovascular mortality in a Chinese population.
Introduction
Cardiovascular disease (CVD) is the leading cause of death worldwide, and the disease burden has increased dramatically in the recent decades in Asia. 1, 2 Among the many risk factors, diet plays important roles in the development and prognosis of CVD. 3, 4 There is a long-standing interest in the plausible cardiovascular benefits of omega-3 fatty acids given the strong effects on several cardio-metabolic pathways (e.g. lipid profile, blood pressure, resting heart rate, endothelial function, platelet aggregation, inflammation, antiarrhythmic effects) from preclinical studies and short-term interventions. 5 Although results on nonfatal cardiovascular events are still conflicting and less well established, evidence from large prospective cohort studies and adequately powered clinical trials has supported the notion that omega-3 fatty acids are associated with reduced risk of CVD mortality. 5 There are two major types of omega-3 fatty acids from the diet: long-chain omega-3 including eicosapentaenoic acid (EPA, C20:5n-3) and docosahexaenoic acid (DHA, C22:6n-3), which are mainly from marinebased foods, and a-linolenic acid (ALA, C18:3n-3) which is mainly plant-derived omega-3 found in seeds, nuts, and their oils. Mounting evidence has suggested that dietary intake of fish and EPA/DHA is associated with a lower risk of CVD mortality, [5] [6] [7] [8] while it is less clear whether ALA also possesses cardiovascular benefits, and results from several prospective studies are mixed. [9] [10] [11] [12] [13] [14] Most studies have been conducted in North American and European countries, and researches in Asian populations are limited. Two cohort studies in Chinese adults and one cohort study in Japanese adults have consistently found an inverse association of fish and EPA/DHA intake with cardiovascular death; however, the results were not consistent with coronary heart disease (CHD) or stroke mortality. [15] [16] [17] Nevertheless, ALA was not examined in those studies. The plant oils have been widely used in Asian cooking, and legumes, soy and grains are major food items in Asian diet. Thus, ALA is a major source of omega-3 fatty acids, but no study has specifically examined the relation between ALA intake and cardiovascular mortality in Asians.
Therefore, we used data from the Singapore Chinese Health Study (SCHS), a population-based prospective cohort of approximately 63,000 Chinese men and women in Singapore. We hypothesized that both EPA/DHA and ALA were associated with a lower risk of cardiovascular death in the Chinese population. We further tested the hypothesis in CVD-free individuals (primary prevention) and people with CVD (secondary prevention) at baseline, as well as the relation with CHD and stroke mortality separately.
Methods

Study population
The design of the SCHS has been described previously. 18 Briefly, 35,303 Chinese women and 27,954 Chinese men aged 45-74 years were enrolled in this population-based cohort study during 1993-1998. All study participants were residents of government housing estates, where 86% of Singaporeans resided at the time of recruitment. This study was approved by the Institutional Review Board at the National University of Singapore, and all participants gave informed consent.
At recruitment, information on demographics, lifestyle factors (physical activity, tobacco use, and alcohol intake), usual diet, and medical history was obtained through in-person interviews using structured questionnaires. We excluded individuals who had baseline cancer (n ¼ 1936) or reported extreme energy intakes (<600 or >3000 kcal/day for women and <700 or >3700 kcal/day for men; n ¼ 1023). The current analysis included 60,298 participants.
Assessment of diet and covariates
A semiquantitative food-frequency questionnaire (FFQ) including 165 commonly consumed food items in this population was administered during baseline interview. The respondents were instructed to select from eight food-frequency categories (ranged from 'never or hardly ever' to 'two or more times a day') and three portion sizes (small, median, large) with the aid of photographs. Relevant to this study, the FFQ listed 14 seafood items, including fresh fish (fish ball or cake, deep fried fish, pan or stir fried fish, boiled or steamed fish), fresh shellfish (shrimp or prawn, squid or cuttlefish), dried/salted fish (salted fish, ikan bilis, dried fish, other dried seafoods such as dried shrimp, dried oyster, dried cuttlefish), and canned fish (canned tuna, canned sardine). The FFQ had been validated subsequently using two 24-h recalls including one weekday and one weekend among a subset of 810 participants from this cohort. 18 The validation study by these two methods showed similar distributions with most mean pairs for energy and nutrients within 10% of each other's values. The correlation coefficient for each dietary component ranged between 0.24 and 0.79, which is comparable with previous validation study in diverse populations. 19 The dietary intake of each nutrient was derived based on the Singapore Food Composition Database. 18 The main dietary sources of EPA and DHA were fish and seafood, while the main dietary sources of ALA were grains (21%), cooking oils (11%), and legumes and soy (9%). Overall, EPA/ DHA accounted for approximately 36% of population omega-3 intake, and ALA made up 64%. Other known or suspected risk factors for CVD were assessed at baseline including age, educational level, smoking status, and physical activity. Body mass index (BMI) was calculated by self-reported body weight in kg divided by square of height in metres. Participants also reported their history of medical conditions diagnosed by physicians, including diabetes, hypertension, CHD, and stroke.
Assessment of mortality
Information on date and cause of death was obtained through linkage with the nationwide registry of birth and death in Singapore to 31 December 2011. As of 31 December 2011, only 47 subjects from this cohort were known to be lost to follow up due to migration out of Singapore or other reasons. This suggests that vital statistics during follow up is virtually complete. Underlying causes of death were coded according to the International Classification of Diseases, ninth revision:codes 390-459 were used for cardiovascular deaths, codes 410-414 for CHD deaths, and 430-438 for stroke deaths.
Statistical analysis
Person-years for each participant were calculated from recruitment to death, lost to follow up, or 31 December 2011, whichever came first. All the nutrients, including omega-3 fatty acids, were adjusted for energy using the residual method. 20 Cox proportional hazard models were used to examine associations between omega-3 fatty acids intake and CVD mortality risk. In the multivariate model, we adjusted for age (continuous), sex, interview year (1993) (1994) (1995) (1996) (1997) (1998) , dialect group (Hokkien, Cantonese), cigarette smoking (years of smoking and number of cigarettes per day), alcohol frequency (never or monthly, weekly, daily), level of education (none, primary school, secondary school or more), moderate physical activity (<0.5, 0.5-3.5, !3.5 h/week), BMI (<20.0, 20.0-23.9, 24.0-27.9, !28.0 kg/m 2 ), history of comorbidities at baseline (diabetes, hypertension, CHD, and stroke), and total energy (continuous). In the final model, we additionally adjusted for dietary variables (in quartiles), including fibre, protein, and all fat subtypes (i.e. omega-6 fatty acids, monounsaturated fat, and saturated fat). When analysing EPA/DHA or ALA, they were included in the model simultaneously.
To examine linear trend, median intake value of each quartile was entered as a continuous variable in the model.
Stratified analysis was made a priori by selfreported history of physician-diagnosed CHD and stroke at baseline. The rationale is to test the hypothesis in primary prevention (participants without CVD history) and secondary prevention (patients with CVD). We further stratified the analysis by baseline diabetes/hypertension in the primary prevention setting to evaluate whether the association persisted in the high-risk group. All statistical analyses were conducted using SAS version 9.1 (SAS Institute, Cary, NC, USA), with two-sided p-value < 0.05 as statistically significant. Table 1 shows the baseline characteristics according to quartiles of omega-3 fatty acids intake. Participants in the highest quartile were slightly younger, more likely to be women, attained higher level of education, and were less likely to be smokers. They also had a higher prevalence of hypertension, diabetes, and CHD. Positive association with omega-3 fatty acids was found with dietary fibre and other fatty acids. No significant differences were found for physical activity and BMI. A similar pattern was found for intake of marine and nonmarine-based omega-3 fatty acids ( Supplementary Table S1 , available online).
Results
We documented 4780 cardiovascular deaths (including 2697 CHD and 1298 stroke deaths) during 890,473 person-years of follow up. In the multivariate model, omega-3 fatty acid intake was monotonically associated with reduced risk of cardiovascular deaths ( Table 2 ). Compared to the lowest quartile, the hazard ratio (HR) for the highest quartile was 0.83 (95% confidence interval, CI, 0.74-0.92, p-trend ¼ 0.003) for total omega-3, 0.86 (95% CI 0.77-0.96, p-trend ¼ 0.004) for EPA/DHA, and 0.81 (95% CI 0.73-0.90, p-trend < 0.001) for ALA. We also tested the joint association between EPA/DHA and ALA with cardiovascular mortality (Figure 1 and Supplementary Table S2 ): compared to those who were in the lowest tertiles of both types, individuals in the highest tertiles had 33% (HR 0.67, 95% CI 0.57-0.78) lower risk. The p-value for multiplicative interaction was not significant (p-interaction ¼ 0.75).
With regard to CHD mortality (Table 3) , significantly inverse associations were found for total, marine, and nonmarine omega-3 fatty acids. For stroke mortality, a trend towards inverse association was observed, but none reached statistical significance.
When we stratified the analysis by self-reported baseline CVD, significant and similar associations were found among individuals who were free of CVD at baseline (Table 4 ). However, among participants with baseline CVD, the associations did not reach statistical significance, although inverse trends were still generally present. The p-value for interaction with baseline CVD was not significant for any of the omega-3 fatty acids (all p-interaction >0.10). A similar pattern was observed for CHD mortality ( Supplementary Table S3 ) and the associations were slightly stronger in people without baseline CVD. For stroke mortality ( Supplementary Table  S4 ), there was a trend towards a lower risk, but the association was not statistically significant for neither EPA/DHA nor ALA. Among participants without baseline CVD, the associations were similar between individuals with or without baseline diabetes/hypertension (all p-interaction >0.10; Supplementary Table S5 ). 
Discussion
In this large cohort study of Chinese men and women, intake of omega-3 fatty acids (both marine and nonmarine-based sources) was independently associated with reduced risk of cardiovascular mortality, particularly CHD deaths. The associations were independent of available established CVD risk factors and other dietary and lifestyle confounders in our database, and the lowest risk was observed in the subjects with high intakes for both EPA/DHA and ALA. The associations were slightly stronger in participants without baseline CVD; however, the interaction was not significant. Our results are largely consistent with previous prospective cohort studies on intake of EPA/DHA and cardiovascular death, 8, 21 including several cohort studies in Asia. [15] [16] [17] In a cohort of 18,224 Chinese men in Shanghai, Yuan et al. 17 reported a 57% lower risk of mortality from myocardial infarction (n ¼ 187 cases) comparing extreme quintiles, but not for stroke (n ¼ 480 cases). In a cohort of 57,972 Japanese men and women, Yamagishi et al. 16 found that participants in the highest quintile of total omega-3 fatty acids intake had 19% lower risk of cardiovascular death (n ¼ 2045 cases), particularly mortality from heart failure (n ¼ 307 cases), but not stroke (n ¼ 972 cases). In another cohort of 134,296 Chinese men and women in Shanghai, Takata et al. 15 observed a 22% lower risk of cardiovascular mortality in women (n ¼ 1090 cases), but not in men (n ¼ 699 cases): EPA/DHA intake was not related to haemorrhagic stroke, and the association with ischaemic stroke was only evident in the highest quintile but not the other categories. Compared to those studies, our analysis has the largest number of cardiovascular deaths (n ¼ 4780), and EPA/DHA was inversely associated with cardiovascular deaths and mortality from CHD, but not with stroke mortality.
Compared to EPA/DHA, studies on the relation between ALA intake and CVD are limited. A recent meta-analysis of six prospective cohort studies in Caucasians reported a 20% lower risk of cardiovascular death comparing top vs. bottom tertiles, 22 although the association was not significant in some included studies. This is probably due to small sample size and limited power (n ¼ 78-829 for outcomes). 22 Again, our study is the largest so far on the association between ALA intake and cardiovascular deaths (n ¼ 4780), and the first report in Asian populations. Our analysis is also one of the few studies that investigated both EPA/DHA and ALA in the same cohort. We found that both types were associated with a lower risk, which is consistent with the Cardiovascular Health Study. 23 One study suggested that ALA intake may particularly reduce CHD risk when EPA/DHA intake is low. 24 But we found that the association appeared to be independent and no significant multiplicative interaction was observed, this is consistent with results from the Nurses' Health Study on risk of sudden cardiac death. 25 The association between EPA/DHA with stroke is less consistent, with modest benefits found in observation cohort studies, but not in clinical trials. 26 In our study, the association between EPA/DHA and stroke mortality was not significant, which is consistent with previous studies in Chinese men 17 and Japanese adults. 16 However, the sample size for stroke outcomes is lower compared to CHD events, and statistical power may be limited. Our study is the first to investigate the relation of ALA intake and stroke risk in Asian populations. The observed inverse association is consistent with a cohort study in The Netherlands, 27 and a nested case-control study in US adults where serum concentrations of ALA were measured in 96 cases and 96 controls. 28 However, null association was also reported in other studies, [29] [30] [31] and further investigations are needed. We are unable to evaluate the association with different types of stroke, and future studies with detailed information of stroke subtypes are warranted.
Recently, several clinical trials have investigated whether EPA/DHA supplements reduce risk of cardiovascular events in the secondary prevention setting. A recent meta-analysis found modest but not statistically significant reductions in cardiac death (9% reduction, 13 trials) and sudden death (13% reduction, seven trials). 32 For ALA supplementation, the Alpha Omega Trial in 4837 CHD patients found no significant effect on major cardiovascular events 33 or highsensitivity C-reactive protein 34 for either EPA/DHA or ALA using a 2-by-2 factorial design with 2 g ALA or 400 mg EPA/DHA as the interventions. In the primary prevention, the ORIGIN 35 trial randomly assigned 12,536 patients who were at high risk for cardiovascular events (individuals who had impaired fasting glucose, impaired glucose tolerance, or diabetes) to receive 900 mg EPA/DHA intervention or olive oil control. No significant reduction was found for cardiovascular death after 6 years. However, use of olive oil as control may mask the benefits from omega-3 fatty acids. Furthermore, participants in the trials were taking more concomitant cardio-protective therapies and may lead to a failure to detect significant benefit with omega-3 fatty acids. 35 Moreover, the statistical power was limited in most trials. 5 No clinical trial has been done in healthy individuals (those without CVD, diabetes, or hypertension) because of low feasibility. Therefore, evidence from both intervention studies and high-quality prospective cohort studies should be considered as evidence for providing dietary recommendations. The risk reduction among patients with existing CVD events in our study was not significant, although the trend was towards a lower risk and no significant interaction was found. This could be due to reverse causation, so that CVD patients may change their diets towards healthy choices at baseline, and also low statistical power in this group. Among individuals without CVD at baseline, our results indicate a similar association in those with or without diabetes/hypertension at baseline, suggesting that omega-3 fatty acids confer cardiovascular benefits in both healthy and high-risk groups.
The strengths of our study include high response and follow-up rate, detailed collection of data through faceto-face interviews, and nearly complete mortality assessment with objectively obtained records. The dietary intake was assessed by a FFQ that was specifically developed and validated in this population, and has been shown to be reasonably accurate. We are also aware of several limitations. First, the dietary intake was self-reported, and some degrees of measurement error were inevitable. However, this would most likely result in nondifferential misclassification with respect to disease status and likely underestimation of association. Second, the self-reported lifestyle-related data and baseline comorbidity status may result in some misclassification and residual confounding. We have adjusted a number of cardiovascular risk factors; however, unmeasured and residual confounding is still possible. Third, we do not have comprehensive data on incident nonfatal cardiovascular events, and future efforts should be made to validate and confirm nonfatal cases. Finally, due to the observational study nature, causality should be made with caution.
In conclusion, our results provide supportive evidence that high dietary intake of both marine and nonmarine-based omega-3 fatty acids is associated with reduced risk of cardiovascular death in the Chinese population, particularly for deaths from coronary heart disease and in individuals without cardiovascular disease at baseline. Further studies are still needed to evaluate the association with incident nonfatal
